Innovent's TED drug meets phase 3 trial primary endpoint
Tweet Send to a Friend
Innovent Biologics (HKEX: 01801) announced that its SYCUME® (Teprotumumab N01 Injection, IBI311) met the primary endpoint in a Phase 3 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




